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A B S T R A C T
Totally implantable vascular access devices (TIVADs) are commonly used in conjunction with enzyme re-
placement therapy (ERT) for lysosomal storage disorders (LSDs). This case series describes potential compli-
cations associated with long-term TIVAD use, such as compromise of skin integrity, infection, or port failures.
Best practices and skilled specialists are essential for minimizing complications from long-term TIVAD use for
ERT.
1. Introduction
A totally implantable vascular access device (TIVAD) is an im-
planted reservoir with a self-sealing silicone septum attached to a sili-
cone catheter that is tunneled under the skin with its tip positioned in a
large central vein. Local anesthetic creams, such as lidocaine/prilocaine
(EMLA®) or tetracaine (Ametop®), are applied to reduce pain and
minimize trauma during Huber needle accessing.
TIVADs were designed for temporary use, but currently, these de-
vices have been utilized for enzyme replacement therapy (ERT) in ly-
sosomal storage disorders (LSDs), including mucopolysaccharidosis
(MPS) disorders, which are lifelong diseases requiring ongoing treat-
ment. Complications of insertion, such as bleeding or bruising, or line
dislodgment, break, or blockage, and complications related to long-
term usage, such as infection and venous thrombosis, must be con-
sidered [1–4]. Additional serious, rare complications, including pneu-
mothorax, hemothorax, pericardial effusion, or cardiac arrhythmias are
also possibilities [3].
The purpose of this case series is to discuss the potential risks when
considering long-term port use for ERT administration.
2. Materials and methods
Individual cases representative of the spectrum of TIVAD-associated
complications in patients with LSDs were selected for presentation,
based on an informal discussion with clinicians from multiple centers. A
group of 64 pediatric patients from Birmingham Children's hospital
with inherited metabolic disorders, including LSDs and general meta-
bolic disorders was included for a general (acute and chronic) assess-
ment of TIVAD complication rate in rare diseases. An additional 33
pediatric patients from Birmingham Children's hospital, exclusively
with LSDs were assessed over the period of January 2007 to December
2014 to determine complications arising from chronic TIVAD use.
TIVADs were inserted into the internal jugular or innominate veins
via an ultrasound-guided percutaneous approach [5] with the port
implanted on the chest wall (e.g., below and lateral to the nipple). The
tip of the line would be positioned in the high right atrium or superior
vena cava/right atrium junction.
3. Results
A summary of 8 selected cases are presented in Table 1.
Patient #1 had a TIVAD inserted in 2011 for weekly hospital-based
ERT for alpha mannosidosis. After 3 years of treatment, along with use
of lidocaine/prilocaine cream, the skin was thinned and discolored, and
a small bruise developed over the TIVAD site. Thereafter, the lidocaine/
prilocaine cream was changed to ethyl chloride spray. No further
changes were seen in skin integrity. In 2016, the patient was admitted
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to his local hospital with a line infection and the TIVAD was removed;
subsequent cannulation was unsuccessful and treatment was dis-
continued.
Patient #2 began ERT by cannulation for MPS II in 2004; the TIVAD
was inserted in 2009 for home infusions with the use of lidocaine/
prilocaine cream. After 2 years and 8months of treatment, a bruise
developed around the TIVAD site, along with signs of skin atrophy and
a small scab over the port. After another 6 weeks, the wound presented
with yellow exudate and the port septum was visible. A skin culture
revealed Staphylococcus aureus. Subsequently, the TIVAD was removed
and reinserted, and the lidocaine/prilocaine cream was changed to
ethyl chloride spray.
Patient #3 began ERT for MPS VI in 2006; the TIVAD was inserted
in 2009 for home infusions with the use of tetracaine cream. However,
the parent overapplied the cream (2 tubes) weekly. After 8months, the
patient was admitted to the hospital; the TIVAD was sitting on the chest
wall with little skin covering the site, likely due to tetracaine burn from
overuse. The TIVAD was removed and reinserted 8months later. The
family was re-educated regarding local anesthetic use, and the therapy
was changed to lidocaine/prilocaine cream.
Patient #4 developed infective endocarditis after 2 years of TIVAD
use for MPS I (attenuated) and required valve replacement. Limited
information was available on this patient.
Patient #5 began ERT for MPS II in 2005; the TIVAD was inserted in
2006 and lasted 8 years, but with intermittent problems. In 2014, the
port site was painful, and the patient felt unwell. Patient had a
thrombus and was treated with warfarin for 3months. The port was
removed in 2015, and the patient is now managed by peripheral infu-
sions.
Patient #6 has MPS II with a history of mitral valve repair. ERT
began in 2007; the TIVAD was inserted in 2008. In 2009, the port was
painful and difficult to flush, but the linogram presented as normal. In
2011, the port failed and was removed. In 2013, a pacemaker was
deemed necessary, after 2 episodes of syncope in the prior 2 years, but 3
attempts at placement failed due to abnormal vessels. On the final at-
tempt, the pacemaker was successfully placed with additional new
equipment and a difficult and lengthy procedure.
Patient #7 began ERT with a TIVAD in 2004, for MPS I (Hurler-
Scheie). She had experienced 3 port failures and reinsertions. In 2013,
she developed severe acute aortic valve incompetence and needed valve
replacement. During an angiogram procedure, her vasculature was
found to be distorted, with collateral venous vessels impinging on ar-
terial vessels.
Patient #8 had slowly progressing MPS VI; the TIVAD was inserted
in 2005 and replaced 1 year later. In 2012, she presented with repeated
episodes of fever. The primary care center was unfamiliar with risks of
port use and made the diagnosis of pneumonia. The patient developed a
fatal, generalized infection.
3.1. Birmingham Children's Hospital Cohort
Patients ranged in age from<3 to 22 years of age, and length of
time with a TIVAD ranged from<2 to> 10 years. Seven of 64 (10.9%)
TIVADs used for weekly ERT were affected by skin integrity compli-
cations; 5 devices required removal.
Of the additional 33 pediatric patients, the most common compli-
cation was difficult port access following weight gain with ERT initia-
tion. Additional complications included 3 port revisions due to line
blockage and 1 early (within 7 days of placement) line infection; no
hemopneumothorax or cardiac problems occurred.
4. Discussion and conclusions
TIVADs are widely used in cancer and cystic fibrosis, and are con-
sidered safe and effective [6,7]. The most common TIVAD-related
complications in patients with cystic fibrosis include occlusion,Ta
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infection, leakage, pain or discomfort, venous thrombosis, stenosis, and
port extrusion [7,8]. In patients with cancer, common TIVAD compli-
cations include infection, sepsis, thrombosis, skin dehiscence, and pain
[6,9,10]. While some overlap exists, the complication profile for TIVAD
use for LSDs is unique.
Due to the characteristics of proteins infused and the clinical nature
of LSDs themselves, patients with LSD might experience a higher rate of
infusion-related reactions than patients treated for other conditions
[11]. In a recent review of TIVAD use in patients with inherited me-
tabolic disorders, the main complications were infection and allergic
reaction [11]. Patients with LSD may have abnormal vasculature as part
of the disease; this may contribute to higher complication rates in these
patients [12–15]. An issue among LSD patients is skin integrity (thin-
ning skin, dimpling, bruising) over the TIVAD sites. Skin erosion at the
implantation site is usually a rare complication of long-term TIVAD use,
with an estimated incidence of 1.67% in patients with average catheter
duration of 335 days [16]. We observed a higher rate of skin compli-
cations (10.9%), which while easier to manage than some complica-
tions, is supportive of skin involvement in LSDs [17].
Because ERT is considered a lifelong therapy, we encourage the use
of peripheral intravenous access; thus, it is important to develop nur-
sing and physician access skills to further this objective. Newer topical
vascular imaging techniques and percutaneous ultrasound vascular
access tools may facilitate placement in very difficult patients [18]. In a
pediatric cohort, use of the ultrasound-guided percutaneous technique
meant that venous occlusion of the great veins (internal jugular, in-
nominate, or superior vena cava) was exceptionally uncommon
at< 3% [19].Additionally, use of distraction techniques during the
procedure can greatly reduce the pain and distress for children and
adolescents [20].
To decrease the risk of complications in patients with LSD who are
using TIVADs for long-term ERT, we recommend following best prac-
tices, such as ultrasound guidance to place central venous catheters
[3–5,21], experienced surgical team and personnel [1,5], hand hygiene
and barrier precautions, and regular examination for thrombus via ul-
trasounds [3,22] and of skin integrity over TIVAD sites. The major long-
term risk for patients with a potentially lifelong requirement for venous
access is occlusion of the great veins and thus consideration should be
made from the start to avoid this occurring by using specialist teams of
surgeons with an interest in vascular access [23] and the ultrasound-
guided percutaneous approach [19,23]. With these measures and
careful placement, monitoring, and confirmation of the need for TIVAD,
specialists will be equipped to strive for optimal outcomes with ERT
with minimal complications from long-term TIVAD use.
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